China Biopsy Market is expected to reach US$ 7.54 Billion by 2027. Since 2000, the number of cancer cases and deaths and the crude incidence and mortality of cancer have continuously climbed in China. Long-term trends in cancer burden and rates reflect patterns in cancer-risk behaviors and changes in medical practice, such as the adoption of cancer screening tests. Furthermore, China is attempting to address its fast-rising cancer burden. However, rising population aging and the cumulative impact of risk factor exposure mean that cancer prevention faces many new obstacles.China Biopsy Market reached US$ 5.24 Billion in 2021. Industry Trends, Growth, Insight, Outlook, Impact of Inflation, Company Analysis, Global Forecast 2023-2027
Trends in China Biopsy Industry Prevailing Currently:
China is transitioning to developed-country cancer profiles, including high breast cancer rates, prostate cancer, lung cancer, liver cancer, thyroid cancer, colon and rectum cancer, kidney cancer, leukemia cancer, pancreatic cancer, and bladder cancer. These developments fuel a push for mass cancer screening and early detection among the 45 to 74-year-old group. As a result, China Biopsy Market Size is expected to expand at a CAGR of 6.25% during 2021-2027.Although imaging procedures such as X-rays and CT scans can help detect areas of concern, they cannot distinguish between malignant and noncancerous cells. Consequently, a biopsy is the only reliable approach to identifying most cancers for cancer diagnosis. To lower the cancer burden in China, biopsy screening technologies and procedures have been developed. However, the most viable option in the near future may be to provide coordinated screening for high-risk locations and opportunistic screening for non-high-risk areas.
Key Companies Insights:
Becton, Dickinson and Company, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Exact Sciences (Genomic Health), Biocept, Biocartis, Roche Diagnostics, Myriad Genetics Inc., Qiagen, NeoGenomics Laboratories, and Quest Diagnostics Inc. are among the important players profiled in our report. These market players in China contribute to market growth by diversifying their cancer diagnostics portfolios, resulting in increased demand for their biopsy test kits.How COVID-19 Affected the China Biopsy Test Industry?
The Coronavirus outbreak hit hard for China's biopsy diagnostics centers, hospitals, supply chain, and clinical trials. In addition, cancer diagnoses were being delayed, as they had been shut since the commencement of the COVID-19 pandemic, as diagnosis services and screening programs were put on halt.Besides, during the pandemic, cancer patients also faced numerous challenges, including increased susceptibility to severe infection and interruptions in treatment or regular medical care. According to our results, the China Biopsy Test Market was negatively impacted from the end of 2019 to the beginning of 2020. However, according to our estimates, China Biopsy Market reached US$ 5.24 Billion in 2021 post recovery from the pandemic scenario.
The publisher's latest report “China Biopsy Market, Forecast By Market, Volume (Biopsy) & Diagnosed (Breast Cancer, Prostate Cancer, Lung Cancer, Liver Cancer, Thyroid Cancer, Kidney Cancer, Leukaemia and Bladder), Application Insights (Market, Volume (Biopsy) and Diagnosed), Companies (Becton, Dickinson and Company, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Exact Sciences (Genomic Health), Biocept, Biocartis, Roche Diagnostics, Myriad Genetics Inc., Qiagen, NeoGenomics Laboratories, and Quest Diagnostics Inc.)” provides a detailed analysis of China Biopsy Industry.
Application Analysis -the Market has been covered from 8 viewpoints:
1. Breast Cancer2. Prostate Cancer
3. Lung Cancer
4. Liver Cancer
5. Thyroid Cancer
6. Kidney Cancer
7. Leukaemia
8. Bladder
Furthermore, the above mentioned application analysis have been covered from 3 viewpoints:
1. Market2. Volume (Biopsy)
3. Diagnosed
Company Insights:
- Overview
- Initiatives/Recent Developments
- Financial Insight
Companies Covered:
1. Becton, Dickinson and Company2. Thermo Fisher Scientific Inc
3. Bio-Rad Laboratories
4. Exact Sciences (Genomic Health)
5. Biocept
6. Biocartis
7. Roche Diagnostics
8. Myriad Genetics Inc.
9. Qiagen
10. NeoGenomics Laboratories
11. Quest Diagnostics Inc.
Table of Contents
Companies Mentioned
- Becton, Dickinson and Company
- Thermo Fisher Scientific Inc
- Bio-Rad Laboratories
- Exact Sciences (Genomic Health)
- Biocept
- Biocartis
- Roche Diagnostics
- Myriad Genetics Inc.
- Qiagen
- NeoGenomics Laboratories
- Quest Diagnostics Inc.
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | October 2022 |
Forecast Period | 2022 - 2027 |
Estimated Market Value ( USD | $ 5.53 Billion |
Forecasted Market Value ( USD | $ 7.54 Billion |
Compound Annual Growth Rate | 6.4% |
Regions Covered | China |
No. of Companies Mentioned | 11 |